Pro-Dex (PDEX) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pro-Dex (PDEX) has outperformed Profound Medical (PROF) over the past year, gaining 92.9% versus a gain of 6.2%. Over five years, PDEX leads with a +180.2% price change compared with -43.6% for PROF. Profound Medical is the larger company by market cap ($233.7 million vs $201.6 million), about 1.2 times the size.
Pro-Dex converts more of its revenue into profit, with a net margin of 17.6% versus -264.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDEX | PROF |
|---|---|---|
| Share price | $63.00 | $6.38 |
| Market cap | $201.60M | $233.68M |
| 1-day change | -0.77% | -3.19% |
| YTD return | +63.72% | -18.93% |
| 1-year return | +92.90% | +6.16% |
| 5-year return | +180.25% | -43.64% |
| P/E ratio (TTM) | 17.36 | — |
| Forward P/E | 18.16 | — |
| EPS (TTM) | $3.63 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $77.55M | $16.10M |
| Revenue growth (YoY) | +16.45% | +50.73% |
| Net income (latest FY) | $13.66M | $-42.57M |
| Gross margin | 31.38% | 70.77% |
| Operating margin | 16.75% | -256.27% |
| Net margin | 17.62% | -264.44% |
| 52-week high | $77.00 | $8.95 |
| 52-week low | $32.14 | $4.80 |
| Distance from 52-week high | -18.18% | -28.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +26.98% | +74.61% |
| Average volume | 54.15K | 208.29K |
| Shares outstanding | 3.20M | 36.63M |
| Employees | 201 | 162 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDEX has outperformed PROF by 86.7 percentage points over the past year.
- Pro-Dex is more profitable, keeping 17.6 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
- Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +16.45%).
About Pro-Dex
PDEX stock →Pro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide.
Health Care · Medical/Dental Instruments · 201 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
PDEX vs PROF FAQ
Which is bigger, Pro-Dex or Profound Medical?
Profound Medical (PROF) is larger, with a market capitalization of $233.68M compared with $201.60M for Pro-Dex (PDEX).
Which stock has performed better over the past year, PDEX or PROF?
PDEX returned +92.90% over the past 12 months, compared with +6.16% for PROF (price return, excluding dividends). Past performance does not predict future results.
Are Pro-Dex and Profound Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.